LRX Company Overview, Contact Details & Competitors

Q: What is LRX's official website and social media links?

LRX's official website is lrxapparel.com. LRX has social profiles on LinkedIn.

Q: How many employees does LRX have currently?

LRX has approximately 28 employees.

Q: What technology does LRX use?

LRX's tech stack includes jQuery, Yotpo Reviews, Venmo, POWR, RSS.

Insights

Gathering insights about LRX…

Similar companies to LRX

LRX Tech Stack

LRX uses 8 technology products and services including Facebook Pixel, C3.js, Google Hosted Libraries, and more. Explore LRX's tech stack below.

Facebook Pixel
Analytics
C3.js
Charting
Google Hosted Libraries
Content Delivery Network
Google Fonts API
Font Scripts
Cloudflare Bot Management
Security
Google Tag Manager
Tag Management
X-Content-Type-Options
Web & Portal Technology
HTTP/3
Web & Portal Technology

Media & News

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements
HOUSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on October 10, 2025 the Company received notice from the Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), the Equity Standard Requirement. This follows the Company's announcement on September 9, 2025 that it had regained compliance with Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Price Requirement.
Oct 13, 2025 | www.globenewswire.com
Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split
HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it will effect a 1-for-15 reverse stock split at 5:00 p.m. Eastern Time, on August 15, 2025. Beginning with the opening of trading on August 18, 2025, Salarius' common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 79400X503.
Aug 14, 2025 | www.globenewswire.com
Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard
HOUSTON, July 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on July 10, 2025 the Company received notification from The Nasdaq Stock Market LLC (Nasdaq) of an additional extension to regain compliance with Nasdaq Listing Rule 5550(b)(1) (Equity Standard) by late July 2025. As previously disclosed, Salarius must also regain compliance with Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement) by early August 2025.
Jul 14, 2025 | www.globenewswire.com
Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies
Phase 1/2 clinical study evaluating seclidemstat in patients with MDS and CMML is progressing with updates expected later this year Company continues to advance its contemplated merger with Decoy Therapeutics HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that two animal studies recently published in peer-reviewed journals provide additional insight into the role of inhibiting lysine-demethylase 1 (LSD1 or KDM1A), a well-validated target in hematologic and solid tumors. Salarius' seclidemstat (SP-2577) is a first-in-class, orally bioavailable LSD1 inhibitor that is being evaluated in an investigator-initiated Phase 1/2 clinical study at MD Anderson Cancer Center (MDACC) as a potential treatment for myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) in patients with limited treatment options.
Jul 09, 2025 | www.globenewswire.com
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board
Decoy's development of novel peptide-conjugate therapeutics arising from its proprietary IMP3ACT™ platform to benefit from Dr. Langer's extensive scientific knowledge and experience Decoy's development of novel peptide-conjugate therapeutics arising from its proprietary IMP3ACT™ platform to benefit from Dr. Langer's extensive scientific knowledge and experience
Apr 16, 2025 | www.globenewswire.com
Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update
Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating respiratory viruses and cancer
Mar 24, 2025 | www.globenewswire.com
Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers
HOUSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that patient enrollment will resume in the investigator-initiated Phase 1/2 clinical trial evaluating seclidemstat in combination with azacitidine for the treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The trial is being conducted at the University of Texas MD Anderson Cancer Center (MDACC) and is listed as recruiting on clinical trials.gov – trial NCT04734990.
Feb 03, 2025 | www.globenewswire.com

LRX's Email Address Formats

LRX uses at least 1 format(s):

LRX Email Formats	Example	Percentage
First@lrxapparel.com	John@lrxapparel.com	50%
First@lrxapparel.com	John@lrxapparel.com	50%

Frequently Asked Questions

Where is LRX's headquarters located?

LRX's main headquarters is located at Marysville, Ohio 43040 US. The company has employees across 4 continents, including North AmericaSouth AmericaAsia.

What is LRX's stock symbol?

LRX is a publicly traded company; the company's stock symbol is SLRX.

What is LRX's official website and social media links?

LRX's official website is lrxapparel.com and has social profiles on LinkedIn.

What is LRX's NAICS code?

LRX's NAICS code is 44-45 - Retail Trade.

How many employees does LRX have currently?

As of October 2025, LRX has approximately 28 employees across 4 continents, including North AmericaSouth AmericaAsia. Key team members include A/R Supervisor: V. B.. Explore LRX's employee directory with LeadIQ.

What industry does LRX belong to?

LRX operates in the Retail industry.

What technology does LRX use?

LRX's tech stack includes Facebook PixelC3.jsGoogle Hosted LibrariesGoogle Fonts APICloudflare Bot ManagementGoogle Tag ManagerX-Content-Type-OptionsHTTP/3.

What is LRX's email format?

LRX's email format typically follows the pattern of First@lrxapparel.com. Find more LRX email formats with LeadIQ.

When was LRX founded?

LRX was founded in 2017.

Insights

Similar companies to LRX

Fabletics

Outdoor Voices

Gymshark

ALO

Nike

Under Armour

Vuori

lululemon

阿迪达斯

LRX Tech Stack

Media & News

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard

Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

LRX's Email Address Formats

Frequently Asked Questions

Where is LRX's headquarters located?

What is LRX's stock symbol?

What is LRX's official website and social media links?

What is LRX's NAICS code?

How many employees does LRX have currently?

What industry does LRX belong to?

What technology does LRX use?

What is LRX's email format?

When was LRX founded?

LRX

Company Overview

Media & News

Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements

Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split

Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?